Raipur: Chhattisgarh is rapidly positioning itself as a leading pharmaceutical and biotechnology hub in central India, attracting investment commitments worth ₹7.83 lakh crore across sectors including pharma, healthcare, and allied industries. The state government is leveraging a high-incentive industrial policy, a dedicated pharma park at Nava Raipur, and expanding healthcare and manufacturing infrastructure to promote industrial growth and employment.
“Our objective is to convert investment intent into time-bound execution. Pharmaceuticals and biotechnology are priority sectors under our industrial growth strategy, and our incentive framework ensures investors recover a significant portion of their capital while establishing globally competitive manufacturing operations,” said Rajat Kumar, Secretary, Industry, Government of Chhattisgarh.
High-Incentive Industrial Policy for Pharma and Biotechnology
Under the Industrial Development Policy 2024–30, pharmaceuticals and biotechnology have been identified as thrust sectors. Eligible projects can avail of industrial investment incentives up to 100% of eligible fixed capital investment, including reimbursement of net State GST for up to 12 years, subject to prescribed limits, or opt for fixed capital investment grants.
Key incentives under the policy include:
- Pharmaceutical projects with ₹50–200 crore investment: Capital grants up to ₹60 crore.
- Projects investing ₹200–500 crore: Grants up to ₹150 crore.
- Investments above ₹500 crore: Capital grants up to ₹300 crore.
- Additional benefits: 100% exemption from electricity duty for 12 years, stamp duty exemption, relief on registration charges, and 50% reimbursement of charges for new electricity connections.
- Projects above ₹1,000 crore: Eligible for customized incentive packages.
This comprehensive framework is designed to encourage large-scale pharmaceutical manufacturing, including formulations, APIs, contract research, medical devices, and AYUSH products.
Read also: Chhattisgarh Records ₹7.83 Lakh Crore Investment Since Nov 2024, CM Sai Highlights Inclusive Growth
Nava Raipur Pharma Park – A Plug-and-Play Manufacturing Hub
A key anchor for the sector is the 142-acre dedicated pharma park at Nava Raipur, being developed as a plug-and-play manufacturing cluster. The park will provide common infrastructure such as need-based water supply, effluent treatment plants, and solid waste management facilities, implemented through a public-private partnership (PPP) model.
The park aims to attract national and global pharmaceutical manufacturers, reducing setup time and operational costs, and positioning Chhattisgarh as a central hub for pharma innovation and production.
Skilled Workforce and Supporting Ecosystem
Chhattisgarh boasts a strong talent base with over 50,000 graduates entering the workforce annually from premier institutions including IIT, IIM, AIIMS, NIT, IIIT, and NLU, supplemented by over 100 pharmacy colleges and 300 vocational training centers. This ensures availability of skilled human resources to support the pharma and biotechnology manufacturing ecosystem.
Healthcare and Allied Sector Investments
The state’s focus on pharma is complemented by strategic healthcare infrastructure investments. Notable projects include:
- A 350-bed multi-specialty hospital planned in Bastar.
- The upcoming Bombay Hospital project.
- Multi-specialty hospital investments from Shalby Hospitals.
- Pharmaceutical manufacturing investment by Torrent Pharmaceuticals.
These projects aim to strengthen healthcare services, generate employment, and support the overall pharmaceutical ecosystem in the state.
Chhattisgarh’s Vision for Industrial Growth
With robust industrial policies, plug-and-play infrastructure, and strong talent availability, Chhattisgarh is emerging as a key destination for pharmaceutical and biotechnology investments in India. The state aims to convert its investment commitments into operational projects, boosting regional development, healthcare access, and economic growth, and positioning itself as a central hub for innovation in pharma and biotechnology.
